anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pharmaceutical compositions effective in the treatment of inflammatory infections comprise 0.5 to 10% by weight of heparin (or a salt thereof) and 0.25 to 0.5% by weight of at least one vasoconstrictor selected from naphazoline and compounds of the formula <FORM:1029034/A5-A6/1> in which R represents H or CH3, and R1 and R11 each represent H or OH, for example phenylephrine, ephedrine or adrenaline.  Heparin salts specified are the sodium, calcium, choline and procaine salts.  Excess heparin may be neutralised with a base such as N-methylglucamine.  The compositions may be administered in the form of aqueous solutions, powders, ointments or pills, and may optionally include an antibiotic, e.g. Framycetin sulphate, and a disinfectant, e.g. chlorbutol.
The exact mechanism of the antifungal action of butoconazole nitrate is unknown; however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.

Butoconazole nitrate is an imidazole derivative that has fungicidal activity in vitro against Candida spp. and has been demonstrated to be clinically effective against vaginal infections due to Candida albicans. Candida albicans has been identified as the predominant species responsible for vulvovaginal candidiasis.
The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Patient's will not receive any of the orientation or family messages and no music will be played through the earphones of the device. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.
Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial.
Infectious diseases wield significant influence on global mortality rates, largely due to the challenge of gauging their severity owing to diverse symptomatology. Each nation grapples with its unique obstacles in combatting these diseases. This study delves into three distinct decision-making methodologies for medical diagnostics employing Neutrosophic Hypersoft Set (NHSS) and Plithogenic Hypersoft Set (PHSS), extensions of the Hypersoft set. It introduces state-of-the-art AI-driven techniques to enhance the precision of medical diagnostics through the analysis of medical imagery. By transforming these images into the aforementioned sets, the analysis becomes more refined, facilitating more accurate diagnoses. The study advocates various courses of action, including isolation, home or specialized center quarantine, or hospitalization for further treatment. The novelty in this study utilizes cutting-edge AI methods to enhance medical imaging, transforming them into accurate diagnostic tools, marking a significant change in how infectious diseases are addressed. By combining machine learning and pattern recognition, it offers the potential to overhaul healthcare worldwide, facilitating accurate diagnoses and customized treatment plans, ultimately reducing the global burden of infectious diseases on mortality rates.
The endometrium is a resilient and highly dynamic tissue, undergoing cyclic renewal in preparation for embryo implantation. Cyclic endometrial regeneration depends on the intact function of several cell types, including parenchymal, endothelial, and immune cells, as well as adult stem cells that can arise from endometrial or extrauterine sources. The ability of the endometrium to undergo rapid, repeated regeneration without scarring is unique to this tissue. However, if this tissue renewal process is disrupted or dysfunctional, women may present clinically with infertility due to endometrial scarring or persistent atrophic/thin endometrium. Such disorders are rate-limiting in the treatment of female infertility and in the success of in vitro fertilization because of a dearth of treatment options specifically targeting the endometrium. A growing number of studies have explored the potential of adult stem cells, including mesenchymal stem cells (MSCs), to treat women with disorders of endometrial regeneration. MSCs are multipotent adult stem cells with capacity to differentiate into cells such as adipocytes, chondrocytes, and osteoblasts. In addition to their differentiation capacity, MSCs migrate toward injured sites where they secrete bioactive factors (e.g. cytokines, chemokines, growth factors, proteins and extracellular vesicles) to aid in tissue repair. These factors modulate biological processes critical for tissue regeneration, such as angiogenesis, cell migration and immunomodulation. The MSC secretome has therefore attracted significant attention for its therapeutic potential. In the uterus, studies utilizing rodent models and limited human trials have shown a potential benefit of MSCs and the MSC secretome in treatment of endometrial infertility. This review will explore the potential of MSCs to treat women with impaired endometrial receptivity due to a thin endometrium or endometrial scarring. We will provide context supporting leveraging MSCs for this purpose by including a review of mechanisms by which the MSC secretome promotes regeneration and repair of nonreproductive tissues.
The invention comprises esters of the b-racement or b - antipodes of a  - phenyl-a -piperidyl-(2)-acetic acid with an alkanol having 3 or 4 carbon atoms which is branched at the carbinol carbon atom, and physiologically tolerable acid addition salts of those esters.  The compounds of the invention may be prepared by reacting the b-racement or a b-antipode of the acid with the alcohol in the presence of a Lewis acid such as hydrochloric, sulphuric or an arylsulphonic acid, an acid chloride or boron trifluoride.  The tertiary butyl ester may be prepared by reacting the acid with iso-butylene, preferably in the presence of a catalyst such as a Lewis acid.  The b-racemate may be resolved into the b1- and b2-antipodes by the use of optically active acids or by biochemical methods.  The b-racemate and b-antipodes of a -phenyl-a -piperidyl-(2)-aceti acid are prepared by hydrogenating a -phenyl-a -pyridyl-(2)-acetamide to produce a -phenyl-a -piperidyl-(2)-acetamide as a mixture of a- and b-racemates, converting the a-racemate to the b-racemate by heating with potassium hydroxide and hydrolysing the amide with sulphuric acid, or converting the mixture of a- and b-racemates of the amide into substantially pure a-racemate by treatment with dry hydrogen chloride, resolving the base into the a1- and a2-antipodes and converting the a1- and a2- antipodes into the b1- and b2-antipodes and hydrolysing these to the acids.ALSO:Pharmaceutical preparations comprise an ester of the b-racemate or a b-antipode of a -phenyl - a - piperidyl - (2) - acetic acid with an alkanol having 3 or 4 carbon atoms which is branched at the carbinol atom, or an acid addition salt thereof, in admixture a conjunction with a pharmaceutical carrier suitable for enteral or parenteral administration.  Examples are given of a preparation of a solution for parenteral administration, an elixir and uncoated and coated tablets, the last-named containing the active ingredient in both the coating and core and showing slow disintegration in the lower gastro-intestinal tract.  The active ingredient in the coating may be replaced by the methyl a -phenyl-a -piperidyl-(2)-acetate hydrochloride.  The preparations in unit dosage form contain between 0.05 g. and 0.20 g. of active ingredient.
BACKGROUND: Blood-brain barrier (BBB) could aggravate cerebral ischemia injury. Dexmedetomidine (Dex) has been believed to play a protective role in cerebral ischemia injury-induced BBB injury.
METHODS: Middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation (OGD) models were established to simulate cerebral ischemia injury. Animal experiments included 4 groups, Sham, MCAO, MCAO+Dex, MCAO+Dex+sh-CCN1. Generally applicable gene set enrichment analysis was performed to analyze gene expression difference. Total collagen content and Evans blue staining were performed to measure infarct ratio and BBB breakdown, respectively. The cell apoptosis, mRNA and protein expression were measured through flow cytometry, PCR, and western blotting, respectively. The levels of IL-1β, TNF-α, and IL-6 in serum were measured with commercial ELISA kits.
RESULTS: Dex greatly promoted the expression level of CCN1. Dex suppressed cerebral ischemia injury, increased tight junction protein expression, improved the memory ability and neurological function of MCAO rats through targeting CCN1. The significant increase of inflammatory factors in the serum of MCAO rats were suppressed by Dex. Dex suppressed OGD induced increase of HRP permeability and promoting tight junction protein expression in vitro through regulating CCN1. The neurological function evaluation was performed with Neurological Severity Score (NSS) and Longa Score Scale.
CONCLUSIONS: Dex could remarkably alleviate cerebral ischemia injury by inhibiting BBB breakdown, inflammatory response, and promoting neurological function and tight junction protein expression via up-regulating CCN1. This study might provide a novel therapeutic target for the prevention and treatment of cerebral ischemia injury-induced BBB.
Subjects with advanced solid tumors will be enrolled in dose escalation cohorts. Dose escalation of HS-10370 will be done to determine maximum tolerated dose.
BACKGROUND AND AIMS: Experimental studies linked dysfunctional Farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) signaling to liver disease. This study investigated key intersections of the FXR-FGF19 pathway along the gut-liver axis and their link to disease severity in patients with cirrhosis.
METHODS: Patients with cirrhosis undergoing hepatic venous pressure gradient measurement (cohort-I n = 107, including n = 53 with concomitant liver biopsy; n = 5 healthy controls) or colonoscopy with ileum biopsy (cohort-II n = 37; n = 6 controls) were included. Hepatic and intestinal gene expression reflecting FXR activation and intestinal barrier integrity was assessed. Systemic bile acid (BA) and FGF19 levels were measured.
RESULTS: Systemic BA and FGF19 levels correlated significantly (r = 0.461; p < 0.001) and increased with cirrhosis severity. Hepatic SHP expression decreased in patients with cirrhosis (vs. controls; p < 0.001), indicating reduced FXR activation in the liver. Systemic FGF19 (r = -0.512, p < 0.001) and BA (r = -0.487, p < 0.001) levels correlated negatively with hepatic CYP7A1, but not SHP or CYP8B1 expression, suggesting impaired feedback signaling in the liver. In the ileum, expression of FXR, SHP and FGF19 decreased in patients with cirrhosis, and interestingly, intestinal FGF19 expression was not linked to systemic FGF19 levels. Intestinal zonula occludens-1, occludin, and alpha-5-defensin expression in the ileum correlated with SHP and decreased in patients with decompensated cirrhosis as compared to controls.
CONCLUSIONS: FXR-FGF19 signaling is dysregulated at essential molecular intersections along the gut-liver axis in patients with cirrhosis. Decreased FXR activation in the ileum mucosa was linked to reduced expression of intestinal barrier proteins. These human data call for further mechanistic research on interventions targeting the FXR-FGF19 pathway in patients with cirrhosis.
CLINICAL TRIAL NUMBER: NCT03267615.
PURPOSE:To provide a plaster drug for transcutaneous administration, free from development of skin irritation and dermatic disorder and capable of keeping the adhesively even in sweat state, by compounding a drug component to a substrate component composed of a lipophilic polymer, a water-soluble polymer and an epoxy compound. CONSTITUTION:The objective plaster drug can be produced by compounding (A) 0.01-15pts.(wt.) (based on 100pts. of plaster) of a transcutaneous absorption drug to a substrate component composed essentially of (B) 52-99.4pts. of a lipophilic polymer preferably exhibiting stickiness at normal temperature (e.g. natural rubber, liquid paraffin, acrylic acid polymer, etc.), (C) 0.5-30pts. of a water-soluble polymer reactive with epoxy group at normal temperature and having carboxyl group or hydroxyl group as functional group and (D) 0.01-3pts. of an epoxy compound having >=2 epoxy groups in the molecule. Sweat can be completely absorbed by the agent and the absorbed sweat does not lower the stickiness of the plastic nor suppress the release of the active drug component.
On Day 1, each subject will receive a single oral dose of 12 mg CTP-543. Following a washout on Day 2, each subject will receive an oral dose of 200 mg fluconazole once daily on Days 3 through to Day 8. On Day 7, approximately 1 hour after the 200 mg dose of fluconazole, each subject will receive a single oral dose of 12 mg CTP-543.
Obstructive sleep apnea is defined as a repetitive collapse of the pharynx during sleep (Malhotra, et al. 2012) which cases intermittent hypoxia. Snoring, witnessed apnea, fatigue and morning headache are symptoms of the disease which has severe health effect (Malhotra. et al. 2012) including increased mortality (Ensrud. et al. 2012) and effects on quality of life (Kuhn. et al. 2017). Hence, identifying and treat obstructive sleep apnea are important.

Obesity, male sex and age are all risk factors for obstructive sleep apnea (Schwartz et. al. 2010, Edwards. et. al. 2010) . Bariatric surgery is known to be a good treatment to achieve a sustained weight loss but the long term effects of bariatric treatment of obstructive sleep apnea is not well studied. The aim of this study is therefore to study the long effects of bariatric surgery as a treatment for obstructive sleep apnea and to find predictors that can be used to predict the severity of the disease.

Eighty-six patients with obesity have been recruited at the Catholic University hospital in Rome, Italy during 2012 when patients were enrolled during their evaluation for bariatric surgery. At baseline, the patient underwent fasting blood chemistry, anthropometric measurements and overnight polysomnography. The patients also underwent a 3 hour oral glucose tolerance test in order to determinate glucose tolerance (normal glucose tolerance, impaired glucose tolerance and type 2 diabetes mellitus). Patient then received treatment with bariatric surgery (gastric sleeve, biliopancreatic diversion or gastric bypass) during 2012-2013 or decided not to undergo bariatric surgery.

Patient will undergo follow-up during 2016-2017 where fasting blood chemistry, anthropometric measurements and overnight polysomnography will be assessed. The patient will also undergo a 3 hour oral glucose tolerance test.

The effects of bariatric surgery on obstructive sleep apnea will then be evaluated. Differences in the treatment effect between the different bariatric surgical procedures will be studied. Patients characteristics at baseline, such as weight, height, BMI and components of the metabolic syndrome and their association to the severity of obstructive sleep apnea will be studied in order to find predictors for the severity of the disease.
BACKGROUND: Cesarean scar pregnancy (CSP), a rare iatrogenic form of ectopic pregnancy (EP), cause of severe maternal morbidity. Each subtype of CSP needs different treatment and there is no consensus about this topic. Despite improvements, the lack of universally accepted therapeutic management and discordance present in literature indicates that treatment has been mainly based on experiences reported.
METHODS: A case series of our double combined approach with methotrexate (MTX) administration followed by vacuum aspiration or resectoscopic approach was reported, with an overview of literature. Eleven patients with CSP underwent a double-step treatment: systemic MTX therapy followed by vacuum aspiration or by resectoscopy, if the gestational sac was embedded deeply in myometrium. For CSP type 1, according to Delphi sonographic classification, with minor potentially risk of complications with a myometrial thickness >3.5 mm, we preferred to adopt vacuum aspiration, while type 2-3 of CSP and myometrial thickness ≤3.5mm were managed with resectoscopy.
RESULTS: The average gestational age was 59.1±7.22 days. On the seventh day after MTX administration, the serum β hCG levels decreased in 80% of all patients. After the MTX injection, the CSP mass did not disappear in any patient. MTX therapy was followed by vacuum aspiration in six and by resectoscopy in five cases. In one case bleeding was controlled by Foley balloon treated with vacuum. In type II-III, CSP was performed UAE (uterine artery embolization) followed by resectoscopy procedure.
CONCLUSIONS: Compared with the results in previous studies, MTX administration followed by suction curettage was more effective than dilatation and curettage and systemic MTX in treatment of CSP. We consider very useful this procedure in case of slow absorption and when the camera was embedded deeply in myometrium (CSP2-3), because that hysteroscopy evaluation of uterine cavity under direct vision is highly accurate in identifying the real cleavage of the gestational camera. We have only used vacuum aspiration in CSP type 1 for minor risk of bleeding.
This is a Treatment clinical trial, randomized, controlled, parallel, double-blinded, with four groups, that aims to evaluate the best application strategy when using a new Universal Adhesive system, Ambar Universal (FGM, Joinville, Brazil). Volunteers will be selected and recruited,following inclusion criteria and pre-established exclusion. All volunteers will be informed and sign a term of clarification and consent. All 38 enrolled patients will receive Class V dental restorations, made in four different ways, one from each experimental group, using the same universal self-etching adhesive system, which is the tested material in this study. All patients must have at only 20 teeth in function, must have at only 4 non carious cervical lesions (NCCL), in different teeth, that need restoration. Those lesions must be non carious, must be more than 1 mm deep, should have exposed dentin, and must have at only 50% of margins in enamel. Teeth should not present periodontal mobility. Firstly, the patient will be anesthetized locally with 3% Mepivacaine solution, followed by prophylaxis with pumice powder and water. All cavities will be washed and dried after these procedures for optimal selection of color, using a color scale. Then, the rubber dam isolation of the teeth to be restored will be held. Non-carious cervical lesions will receive the applied adhesive system in 4 different protocols separated by groups. Group SET (control): no conditioning, the adhesive system will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; Group SEE (Selective enamel etching): 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be applied according to the manufacturer's instructions, as described in group SET; Group SETT: Similar to Group SET, but during the 2 applications, the adhesive systems will be brushed during 20 seconds, and not during 10 seconds as described in Group SET; Group SETL: The adhesive system will be applied as describe in Group SET, but the researchers will apply 4 layers, and not 2 layers, as described in Group SET. After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores. To determine in which group each tooth will be enrolled, the authors will randomize the teeth.
PURPOSE:To obtain a calcitonin pharmaceutical easily administrable of the noninjection type, by dispersing calcitonin with an amino acid derivative in a suppository base. CONSTITUTION:A calcitonin pharmaceutical for rectal administration prepared by dispersing calcitonin and an amino acid derivative, e.g. sodium N-(1-methyl-2- ethoxycarbonyl-vinyl)-DL-phenylglycinate, in a suppository base, e.g. cacao butter, uniformly. The calcitonin is a single chain polypeptide hormone consisting of 32 amino acids secreted from the thyroid gland of mammals, and acts on the bone, intestinal tract or kidney to reduce the calcium or inorganic phosphorus in blood. Therefore, the pharmaceutical is effective against hypercalcemia, particularly senile osteoporosis, however, has been only used as an injection. The use of the calcitonin with the amino acid derivative in the suppository permits the good absorption by the rectum and facilitates the administration of the calcitonin.
PROBLEM TO BE SOLVED: To obtain an oral cavity composition having improved application feeling, exactly screening the strange taste due to sodium hydrogen carbonate by formulating one or two kinds of specific compounds to a composition for oral cavity containing sodium hydrogen carbonate. SOLUTION: A combination of a salt of glycyrrhizic acid with 1,8-cineole are formulated to an oral cavity composition containing >=5wt.% of sodium hydrogen carbonate. These glycyrrhizic acid salt and 1,8cineole synerigistically act to screen the strange taste of sodium hydrogen carbonate. The glycyrrhizic acid salt is, for example, monoammonium glycyrrhizate or the like and its amount in the formulation is about 0.005-0.5wt.%. The 1,8-cineole is used as a perfume and the essential oil containing this compound may be used as it is and its amount in the formulation is at a level of 0.001-0.5wt.%. This composition may be prepared to mouth wash, chewing gum and the like.